Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia

Neurology. 2006 Dec 26;67(12):2233-5. doi: 10.1212/01.wnl.0000249308.66959.43.

Abstract

In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Botulinum Toxins / immunology*
  • Botulinum Toxins / therapeutic use*
  • Botulinum Toxins, Type A
  • Drug Resistance / drug effects
  • Drug Resistance / immunology*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neuromuscular Agents / immunology
  • Neuromuscular Agents / therapeutic use
  • Torticollis / drug therapy*
  • Torticollis / immunology*
  • United States

Substances

  • Neuromuscular Agents
  • rimabotulinumtoxinB
  • Botulinum Toxins
  • Botulinum Toxins, Type A